RxDoctor Payments Data

Kamilia Nozile-Firth, MD

Neurology · Clearwater, FLNPI 1386908846

Payments from drug & device makers

$38,118in general payments, 2019–2025

Across 629 payments — averaging $60.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Abbott$10K
  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$820
  • MDD US Operations, LLC$747
  • plus $8K from 44 others

What the payments were for

  • Speaking & faculty fees$1750%
  • Grants$25,00066%
  • Travel & lodging$2531%
  • Food & beverage$12,53733%
  • Education$1390%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,118 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$280,715
Medicare patients
291
Services billed
26,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate88$444,357
Austedo XrDeutetrabenazine59$348,283
IngrezzaValbenazine Tosylate25$302,808
GocovriAmantadine Hcl48$151,226
RytaryCarbidopa/Levodopa105$133,341
BotoxOnabotulinumtoxina33$52,039
Carbidopa-LevodopaCarbidopa/Levodopa712$26,275
NeuproRotigotine15$22,228
Rasagiline Mesylate47$6,319
Memantine Hcl89$4,388
Propranolol Hcl ErPropranolol Hcl90$3,978
AmantadineAmantadine Hcl51$3,905
Doxepin Hcl20$3,430
Carbidopa-Levodopa ErCarbidopa/Levodopa71$3,215
Primidone94$3,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,169$444,35788 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$645$348,28359 claims
Neurocrine Biosciences, Inc.Ingrezza$820$302,80825 claims
MDD US Operations, LLCGocovri$747$151,22648 claims
Amneal Pharmaceuticals LLCRytary$355$133,341105 claims
AbbVieBotox$1,662$52,03933 claims
UCB, Inc.Neupro$161$22,22815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →